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Disturbed EEG sleep, paranoid cognition
and somatic symptoms identify veterans
with post-traumatic stress disorder
Harvey Moldofsky, Lorne Rothman, Robert Kleinman, Shawn G. Rhind and J. Donald Richardson
Background
Chronic post-traumatic stress disorder (PTSD) behavioural
symptoms and medically unexplainable somatic symptoms are
reported to occur following the stressful experience of military
combatants in war zones.
Aims
To determine the contribution of disordered EEG sleep
physiology in those military combatants who have
unexplainable physical symptoms and PTSD behavioural
difficulties following war-zone exposure.
Method
This case-controlled study compared 59 veterans with chronic
sleep disturbance with 39 veterans with DSM-IV and clinician-
administered PTSD Scale diagnosed PTSD who were
unresponsive to pharmacological and psychological
treatments. All had standardised EEG polysomnography,
computerised sleep EEG cyclical alternating pattern (CAP) as a
measure of sleep stability, self-ratings of combat exposure,
paranoid cognition and hostility subscales of Symptom
Checklist-90, Beck Depression Inventory and the Wahler
Physical Symptom Inventory. Statistical group comparisons
employed linear models, logistic regression and chi-square
automatic interaction detection (CHAID)-like decision trees.
Results
Veterans with PTSD were more likely than those without PTSD
to show disturbances in non-rapid eye movement (REM) and
REM sleep including delayed sleep onset, less efficient EEG
sleep, less stage 4 (deep) non-REM sleep, reduced REM and
delayed onset to REM. There were no group differences in the
prevalence of obstructive sleep apnoeas/hypopnoeas and
periodic leg movements, but sleep-disturbed, non-PTSD
military had more EEG CAP sleep instability. Rank order
determinants for the diagnosis of PTSD comprise paranoid
thinking, onset to REM sleep, combat history and somatic
symptoms. Decision-tree analysis showed that a specific
military event (combat), delayed onset to REM sleep, paranoid
thinking and medically unexplainable somatic pain and fatigue
characterise chronic PTSD. More PTSD veterans reported
domestic and social misbehaviour.
Conclusions
Military combat, disturbed REM/non-REM EEG sleep, paranoid
ideation and medically unexplained chronic musculoskeletal
pain and fatigue are key factors in determining PTSD disability
following war-zone exposure.
Declaration of interest
None.
Copyright and usage
© The Royal College of Psychiatrists 2016. This is an open
access article distributed under the terms of the Creative
Commons Non-Commercial, No Derivatives (CC BY-NC-ND)
license.
The disabling behaviour symptoms of military combatants, who
were involved in the Viet Nam war, provided the impetus to
characterise those psychological disturbances as post-traumatic
stress disorder (PTSD). This psychiatric diagnosis first appeared
in the third edition of the APA’s Diagnostic and Statistical Manual
(DSM-III), with its seminal feature being a specific precipitating
stressful event. Subsequently, two major revisions of the DSM
better characterised PTSD’s behavioural diagnostic features. There
are three clusters of behaviour symptoms in DSM-IV1 and four
cluster groups in DSM-5.2 These four clusters comprise re-
experiencing, avoidance, negative mood and cognitions (such as
depressive, hostile, aggressive and paranoid thinking), and behavioural
arousal including sleep disturbances. In addition to its behavioural
features, military medical personnel have described a variety of chro‐
nic disabling physical symptoms following exposure to combat.3
These troublesome physical complaints lack any objective phy‐
sical pathology. Where the focus is on unexplained widespread
variable musculoskeletal pain and chronic fatigue, the current
preferred diagnosis is fibromyalgia (formerly known as rheumatism
or fibrositis). This diagnosis overlaps with equally medically
unexplained syndromes such as Gulf War syndrome, chronic
fatigue syndrome, combat fatigue (with previous labels including
Da Costa’s syndrome, disordered action of the heart, neurasthenia
or neuro-circulatory asthenia, and effort syndrome). Patients
with fibromyalgia have unrefreshing sleep with disturbances in
EEG sleep physiology. Moreover, experimentally induced sleep
physiological disturbances in normal individuals and animals result
in increased pain sensitivity and pain symptoms. Clinical and
epidemiological studies show that chronic sleep disturbances are
integral to a vicious self-perpetuating cycle of chronic pain, fatigue,
negative mood and cognition in patients with fibromyalgia. These
symptoms may be precipitated by a distressing traumatic industrial
or motor vehicle accident.4 Therefore, the purpose of this study was
to determine whether the disordered physiology of the sleeping/
waking brain may provide the link between the behavioural and
somatic symptoms of those military personnel experiencing post-
combat chronic PTSD. The analyses comprised a two-part strategy:
first, to establish differences between treatment-resistant PTSD and
non-PTSDmilitary personnel in multiple domains comprising EEG
sleep physiology, behavioural and the medically unexplained pain
and fatigue somatic symptoms; and second, to generate a decision-
tree probability model for PTSD based on these differences. That is,
the key behavioural elements that distinguish chronic PTSD from
non-PTSD military comprise a specific stressful traumatic event
(i.e. combat), altered sleep EEG physiology, persistent unexplained
somatic symptoms and negative cognitive behaviour.
We employed a case-controlled study of PTSD in which both
case and control groups included veterans with and without
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experience in combat zones, enabling us to separate PTSD
symptoms from those that might be associated with combat
experience alone and to assess combat experience along with other
patient measures when building models. We measured behaviour
symptoms, including negative cognition (depressive, hostile,
aggressive and paranoid thinking), and chronic physical health
concerns, including disturbances in EEG sleep physiology, sleep
quality and medically unexplained somatic symptoms (e.g. mus-
culoskeletal pain and fatigue).
Method
Participants
The participants comprise consecutive patients referred between
2008 and 2014 from an Operational Stress Injury (OSI) clinic of
the Department of Veteran Affairs of Canada. The OSI clinic
specialises in the assessment and treatment of PTSD and other
operational stress injuries in the Canadian military and veteran
forces (CF). The diagnosis of PTSD was determined by a psychiatrist
employing a comprehensive psychiatric examination and the
Clinician-Administered PTSD Scale (CAPS) for DSM-IV,5 where
the CAPS mean rating was 77.38 and s.d. 21.36. To control for
commonly disrupted and insufficient sleep problems in the
military, we compared sleep and symptoms in CF veterans with
persistent symptoms of PTSD with CF personnel without a history
PTSD who complained of chronic insomnia. This latter group
of participants were referred from Canadian Department of
National Defence (DND) medical ambulatory clinics for diagnostic
assessment of a possible chronic primary sleep disorder such as
sleep apnoea or restless legs/sleep-related periodic limb movement
disorder.
The participants consented to be assessed in the Centre for
Sleep and Chronobiology in Toronto for specialised comprehen-
sive sleep/wake clinical and laboratory investigations of their
chronic treatment-resistant symptoms. The research was reviewed
and approved by the DND, Institute of Military and Veterans
Research Institute in association with Defence Research and
Development Canada.
Table 1 shows the description of the participants: gender, mean
age, mean BMI and the independent variables: combat experience
(combat 1=yes and 0=no or unknown) and the presence of
treatment-resistant PTSD (1=yes and 0=no) were independent
variables. All patients with PTSD (33 with combat and 6 without)
were referred from the OSI. No patients with PTSD were referred
from the DND (28 with combat and 31 without). There were no
significant differences in the two groups’ ages and BMI values.
There were no females with PTSD in the study. SAS Software
Multivariate Analysis of Variances (MANOVAs) tests showed no
significant gender differences when comparing non-PTSD females
(n=9) with non-PTSDmales (n=50). Both genders were included in
the study. Combat experience included those patients who had
served in combat zones (e.g. Gulf War and Afghanistan) and those
who developed treatment-resistant PTSD symptoms following
deployment to the so-called ‘U.N. peace-keeping missions’ in
dangerous combative environments, that is, the Balkans (Bosnia
and Croatia) and Africa/Middle East (Suez Canal zone, Rwanda,
Somalia and Cyprus). Six cases of PTSD occurred in sleep-
disturbed, non-combat CF patients. Distressing non-combat trau-
matic events were quite varied. They included sexual assault,
witness to a major airplane crash, engagement in dangerous service
with the military police, witness to a suicide of a soldier and
participation in a military training exercise.
All patients with treatment-resistant PTSD (n=39) were
functionally impaired despite psychological and lengthy pharma-
cological treatments (median 32.5 months (range 6–249 months)).
All patients with PTSD had received cognitive–behavioural
treatments, which included trauma-focussed behaviour therapy
such as prolonged exposure and various types of psychological
support, for example, individual, marital, family counselling and
group therapies.
At the time of the sleep study, patients with PTSD were
taking at least two drug class combinations of antipsychotics (e.g.
risperidone, quetiapine, aripiprazole; n=12), various antidepres-
sants (e.g. mirtazapine, bupropion, venlafaxine, citalopram; n=34),
anticonvulsant mood modulators (sodium valproate or topiramate;
n=13), and benzodiazepine sedative hypnotics (n=8). In compar-
ison with the patients with PTSD, the 59 with unremitting sleep
problems and no PTSD used fewer antidepressants (n=16), antic-
onvulsants (n=4), antipsychotics (n=5) and sedative hypnotics
(n=1) (all χ2 test, P<0.05). Table 1 provides a detailed description
of the groups of participants, with and without PTSD, their use of
classes of medications and whether or not they had been exposed to
combat. The medical records that were made available did not
specify the psychotropic medications before their treatments at
the time of the polysomnographic sleep study. In particular, of the
unknown number of individuals who had previously received the
alpha1-adrenergic receptor blocker (prazosin) for disturbing
dreams, only two participants continued to find that this drug
satisfactorily reduced their recurrent nightmares. Moreover, the
psychotropic treatments were not withdrawn to avoid potential
adverse effects and permit full cooperation of the patients to participate
in the various physiological and behavioural proceedings.
In addition, to the psychotropic drugs shown in Table 1, other
medications that were consumed include the following.
. Patients with PTSD received pain medication (opiates: 3;
NSAIDs: 6). Sixteen patients received medication for
Table 1 Sample sizes, participant descriptions and drug use
PTSD – yes PTSD – NO
Combat – yes Combat – no Combat – yes Combat – no
Total number of participants 33 6 28 31
Number of females 0 0 2 7
Number of males 33 6 26 24
Mean age (years) 44.4 46.8 40.5 41.6
Mean BMI 30.1 32.5 30.1 32.5
Drugs
Antipsychotics 9 3 2 3
Antidepressants 27 7 5 11
Anticonvulsants 10 3 2 2
Benzodiazepines 8 0 0 1
Prazosin 2 0 0 0
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cardiovascular problems. Three patients were treated for
type 2 diabetes.
. Those without PTSD were prescribed more NSAIDs
(n=11) and no opiates, but similar cardiovascular drugs
(n=13) and antidiabetic drugs (n=4).
Those individuals who had been previously identified by the
military physicians as having problems with alcohol and/or sub‐
stance abuse/dependency had been treated for their condition(s)
before the time of referral for their sleep study. For this study, all
participants completed a self-rated standardised questionnaire on
the types, amount and frequency of use of alcohol and recreational
drugs over the previous year and during 2 weeks before their sleep
study. During the 2 weeks before the sleep study, neither group
abused alcohol and there were no differences in their alcohol
habits. During the previous year, eight patients with PTSD used
cannabis, whereas none of the patients without PTSD used
cannabis (χ2 test, P<0.01). Within the 2 weeks before the sleep
study, only two patients with PTSD had occasionally taken
cannabis drugs, whereas none in the sleep-disordered group used
cannabis drugs (χ2 test, P=NS).
The individuals with and without PTSD completed psycholo-
gical and physical symptom self-reports before a single overnight
EEG sleep study. Because sleep disturbance has the potential to
promote negative cognitions such as irritability, aggressive beha-
viour, paranoid and depressive thinking that may occur with
PTSD,6–8 we employed the Symptom Checklist-90 (SCL-90) sub-
scales for hostility and paranoid thinking8,9 and the Beck Depres-
sion Inventory (BDI).10 Physical symptoms were self-rated from
1 to 5 with the Wahler Physical Symptom Inventory (WPSI).11,12
The number of symptoms self-rated as 4 or 5 on the WPSI scale
(corresponding to ‘about twice a week’ or ‘nearly every day’) was
tallied to determine the prevalence of troublesome symptoms.
Frequency of regional pain symptoms,13 severity of fatigue (range
from 1 ‘full of energy’ to 7 ‘totally physically exhausted’)14 and
Stanford Sleepiness Scale15,16 were self-rated before and after the
overnight sleep.
The frequency of sleep-related behavioural disturbances during
the previous 2 months was rated on the Sleep–Wake questionnaire
with a graded scale of 0 – 3 (0=never, 1=sometimes, 2=often
and 3=always). The behavioural disturbances during sleep included
frequency of awakening during the night because of nightmares or
unpleasant dreams, told that you had screamed or shouted and
disturbing (bad) dreams during sleep. Abnormal cognition included
self-ratings of frequency of harmful behavioural to self and others
noted in BDI Q9 (10): thoughts of killing self-rated on a scale of 0–3.
Abnormal temper outbursts that could not be controlled included
urges to beat, injure or harm someone; urges to break or smash
things; shouting or throwing things (questions from the SCL-90,
which were rated on a scale of 0–4: 0=not at all, 1=a little bit,
2=moderately, 3=quite a bit, 4=extremely).11
Physiological assessment of sleep comprised standardised
EEG polysomnography (PSG). The PSG included electroencepha-
logram (EEG C3 and C4), electro-oculogram, submental and
bilateral anterior tibialis electromyogram, single anterior lead
electrocardiogram, measures of respiration comprising measures
of airflow with oral–nasal thermistors, respiratory impedance
plethysomography and pulse oximetry. An experienced registered
PSG technologist completed blind ratings of sleep physiological
indices.17,18 The sleep EEG stages were scored according to the
original Rechtschaffen and Kales criteria,17 which were needed for a
computerised physiological sleep measure of EEG sleep stability
known as the Cyclical Alternating Pattern (CAP).19–21 Sleep EEG
CAP is characterised by sequences of transient EEG changes
in non-REM sleep that occur distinctively from the background
EEG activities. They comprise three subtypes: CAPA1 is related
to favourable sleep stability. CAPA2 and CAPA3 are progressive
indices of poor sleep quality or sleep instability.19 These abnormal
physiological features have been observed in patients who have
chronic widespread musculoskeletal pain and fatigue,22,23 as well as
sleep-related breathing disorders.24 Analysis of nocturnal sleep
EEG CAP was determined by an Embla computerised automatic
detection system.21,22
Data analyses
MANOVAs were fit into four groups of dependent variables. These
included PSG and sleep EEG CAP indices; self-ratings of behaviour,
including negative cognition; pre- and post-PSG sleepiness and
fatigue; and physical symptom severity. Combat experiences
(Combat 1=yes, 0=no or unknown) were the independent variables
that were compared to whether or not they had treatment-resistant
PTSD (PTSD 1=yes, 0=no) (see Table 1). Because there were only
six patients with PTSD=1 and Combat=0, we did not test for PTSD
× Combat experience interactions. EEG sleep measures included
sleep architecture and computerised measure of EEG sleep stability,
that is, sleep EEG CAP rate. MANOVA permitted the testing of the
significance of suites of measures, while accounting for relation‐
ships among the dependent variables as well as the relationships
between independent and dependent variables. Initial data explora-
tion showed skewed distributions, and outliers, particularly for
the sleep physiology measures. Normality assumptions were likely
violated. For significance testing, MANOVA and ANOVA models
were fitted to ranked measures; tests on ranked data provided non-
parametric tests.25–28 All inferences were based on these ranked non-
parametric tests. Because multiple testing inflates Type 1 error, or the
probability of rejecting the null hypothesis when true, P-values from
ANOVAs were adjusted for multiple testing within each of the four
independent variable groups by the adaptive step-down Holm
method.29 This method controlled for the error rate within a family
of tests (family-wise error). The test does not assume independence
between the various dependent variables in these ANOVAs.
We used three methods to identify distinguishing character-
istics of PTSD and non-PTSD patients: canonical discriminant
analysis (CDA), logistic regression and decision trees. PTSD was
the dependent variable. Patient measures and combat experience
were the independent variables.
We fitted a chi-square automatic interaction detection (CHAID)-
like decision-tree algorithm by SAS Enterprise Miner.28 The CHAID
approach finds splitting rules that create pure segments of data by a
chi-squared test of association with a significance cut-off (alpha of
0.05), where all P-values are adjusted for multiple testing by a
Bonferroni method. Missing values were addressed through multiple
imputations by the predictive mean matching method, which is more
appropriate for non-normal measures.29,30 BDI was excluded from
decision-tree and regression modelling because this self-rated test
includes both somatic symptoms such as sleep, pain and fatigue, and
abnormal cognitive behavioural data.
Results
Patients with PTSD differed from patients without PTSD in
prevalence of suites of physical and behavioural health problems,
while controlling for the effects of combat exposure. MANOVA
tests showed significant differences between patients with PTSD
and without PTSD on sleep measures (P<0.01), psychological
symptoms self-reports (P<0.0001) and physical symptoms self-
reports (P<0.01). The MANOVA test showed no significant
difference between PTSD and non-PTSD on subtypes of sleep
EEG CAP measures (P>0.05).
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While controlling for the effects of combat exposure, indivi-
dual ANOVAs showed differences between PTSD and non-PTSD
groups in their distributions of onset to EEG sleep, sleep
efficiency, EEG stage 4%, REM sleep onset latency, REM% and
EEG CAP indices measures including CAP frequency, CAPA2,
CAPA3/CAPA1+A2+A3
22 (see Table 2). Those with PTSD took
longer to fall asleep, had less efficient sleep (i.e. less time asleep
relative to time in bed), less deep (stage 4) sleep, lower percent of
time in REM sleep and a prolonged delay to onset of REM sleep.
The higher CAP frequency index in the non-PTSD group is
consistent with their complaint of chronic poor quality of sleep in
the absence of a specific combat-related traumatic experience.
These sleep EEG differences may be influenced by more frequent
use by the PTSD group of psychotropic drugs.
There were no group differences in prevalence of primary sleep
disorders such as obstructive sleep apnoea or sleep-related periodic
leg movements (PLM). The prevalence of patients with PTSD with
an index of obstructive sleep apnoeas/hypopnoeas per hour of sleep
>5 per hour (n=35) did not differ from patients without PTSD
(n=25, χ2=NS). Furthermore, there were no statistical differences
in their frequencies of sleep EEG arousals from sleep apnoea/
hypopnoeas or with sleep-related PLM (see Table 2).
Behavioural disturbances during sleep were more common
among the PTSD veterans. Of the 39 patients with PTSD, 32 were
more likely to be awakened by nightmares versus 11 of 59 patients
without PTSD (χ2 test, P<0.05). Twenty-one patients with PTSD
versus six patients without PTSD reported screaming or shouting
during sleep (χ2 test, P<0.05). Seven of those in the combat-related
PTSD group also reported inadvertently striking, but not seriously
injuring, their partner during sleep, whereas none of the non-
PTSD group described any abnormal sleep-related behaviour.
Patients with PTSD had greater mean ratings on the WPSI
with more frequent physical problems (commonly musculoskele-
tal pain and post-sleep fatigue) (Table 3).
Patients with PTSD described significantly more BDI depres-
sive symptoms (see Table 4). Further, seven patients with PTSD
reported suicidal intentions, whereas none of the patients without
PTSD reported suicidal intentions.
More patients with PTSD reported hostility and paranoid
notions on the SCL-90 (Table 4). Nineteen participants reported
domestic and/or violent social behaviour with three being charged
and arrested for assaultive behaviour. In contrast, none of the
non-combat non-PTSD patients reported any form of social
misbehaviour (χ2 test, P<0.001).
CDA and, in particular, logistic regression and decision trees
identified the most salient combinations of measures that
characterise PTSD. All five runs of CDA, which used multiply
imputed data sets, showed significant discriminant functions
(P<0.001). Excluding combat exposure, the top six variables that
are most correlated (|r|>0.4) with these functions and were the
most discriminating characteristics of PTSD, comprise the follow-
ing features: BDI total score, paranoid score, REM onset latency,
SCL-90 hostility scale score, WPSI symptom score and reduced
REM% sleep. Regression models that minimise Schwarz criteria
reveal that PTSD is described by REM onset latency, paranoid
score and combat exposure. Individuals with combat experience
had 4.7 times the odds of having PTSD compared to those without
combat exposure. Because selective serotonin reuptake inhibitor
(SSRI) and serotonin-noradrenaline reuptake inhibitor (SNRI)
antidepressants may cause a delay in REM onset latency31 and
both antipsychotic as well as anticonvulsant neurotropic drugs
may influence EEG sleep physiology, we also re-ran the selection
routine while forcing these drugs as variables into the model. The
selection routine chose the same variables. PTSD in these
individuals is still described by REM onset latency, paranoid score
and combat exposure, even while controlling for the use of
antidepressant, antipsychotic and anticonvulsants.
The CHAID-like decision-tree analysis reveals the key traits
that distinguish PTSD from non-PTSD and their relative impor-
tance. Paranoid score was the most important variable in the tree
model, followed by REM onset latency, exposure to combat and
WPSI severity score based on each measure’s contribution to
impurity reduction across the tree (relative importance: 1, 0.79,
0.77 and 0.49, respectively). For individuals who were exposed
to combat, longer delays to onset of REM sleep (REM onset
latency≥175.5 min) lead to higher propensity of exhibiting PTSD
(0.79 or 79%). Lower REM onset latency and high paranoid scores
(≥7.5) lead to high PTSD propensity (0.857 or 85.7%), whereas
low paranoid scores (<2.5) lead to low PTSD propensity. With no
combat experience, PTSD is still highly probable (0.83 or 83%)
with higher paranoid scores (≥2.5) and higher somatic symptom
ratings (WPSI≥11). On the other hand, those non-combat in‐
dividuals with lower paranoid and somatic symptom ratings were
likely to have a low propensity for PTSD (see Fig. 1).
Table 2 Results of ANOVAs sleep physiology measures
PTSD
No Yes
Dependent LSM SE n LSM SE n P
Sleep onset latency (min) 11.9 1.81 58 17.38 2.47 38 <0.05
Sleep efficiency (%) 85.5 2.05 58 81.19 2.81 38 <0.05
Stage 1 (%) 12.36 1.7 58 14.56 2.32 38 NS
Stage 2 (%) 61.76 1.36 57 66.31 1.84 38 NS
Stage 3 (%) 6.33 0.78 57 5.74 1.06 38 NS
Stage 4 (%) 2.01 0.44 56 0.91 0.61 36 <0.05
REM (%) 19.14 0.93 57 11.66 1.26 38 <0.0001
REM onset latency (min) 124.91 10.61 56 205.9 14.69 35 <0.001
Apnoea–hypopnoea arousals 74.73 15.92 57 109.6 21.79 37 NS
PLM arousals 17.57 5.16 57 32.98 7.27 36 NS
Spontaneous arousals 51.48 4.62 58 45.25 6.38 37 NS
CAPA2 Index Cycle 7.07 0.74 56 5.49 1.01 37 NS
CAPA3 Index Cycle 9.16 0.99 56 6.01 1.34 37 NS
CAPA1/CAPA1+A2+A3 0.25 0.02 56 0.24 0.03 37 NS
Total CAP Index Cycle 74.77 4.23 56 57.83 5.75 37 <0.05
All P-values from ranked (non-parametric) tests are adjusted by the adaptive Holm method to control family-wise error rate. Least-square means (LSM) for PTSD, no (0) and yes (1), are
adjusted to remove combat effects. Bold denotes significance.
Moldofsky et al
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Discussion
This study provides provisional evidence for the key clinical
and physiological sleep features that characterise veterans who
remain functionally disabled with PTSD despite various drug and
behavioural treatments. The results are consistent with DSM-V
behavioural symptomology. The association of malfunctions of
the sleeping/waking brain and medically unexplained physical
symptoms with DSM-IV behavioural symptoms, identified in the
MANOVA and CDA analyses, broadens our understanding of
chronic PTSD. These psychological and somatic symptoms are
consistent with our hypothesis that EEG sleep disturbances may
provide the link between negative cognition and mood, and somatic
symptoms. While ANOVA and MANOVA statistics show these
symptoms to be independent of combat stressor effects, the war-
zone experience itself is a key characteristic of PTSD among
military personnel, as shown by both the logistic regression and
decision-tree models (see Fig. 1). Our decision-tree model in
Fig. 1 shows that combat military service, disturbed REM sleep,
paranoid thinking and medically unexplainable somatic symptoms
(commonly musculoskeletal pain) characterise CF veterans with
chronic PTSD. However, the regression model, while identifying
combat and altered EEG sleep, did not include somatic symptoms.
Our EEG sleep results complement previous studies that show
the importance of disturbances in REM and non-REM sleep.
Those with chronic PTSD take longer to fall asleep, have reduced
sleep efficiency, reduced stage 4 (deep) sleep, reduced and delayed
onset to REM sleep.32–35 A meta-analysis of previous polysomno-
graphic studies of military and civilian patients with PTSD versus
those without PTSD showed similar findings with more stage 1
(light) sleep, less slow-wave (deep) sleep and alterations in REM.34
Furthermore, our findings are consistent with previous PTSD
sleep studies, which show prolongation in the onset to REM
sleep.35,36 The higher EEG CAP frequency in the patients without
PTSD, a sensitive marker for sleep instability,19 may be related to
their primary complaint of disturbed and unrefreshing sleep. Such
differences in EEG CAP frequency are unlikely to be affected
by psychotropic drugs, which reduce EEG CAP rate.37 Unlike
previous studies that associate sleep-related breathing disorders to
sleep EEG CAP24 and to PTSD in the military,35 this study found
no statistical differences in apnoea/hypoponea index, sleep-related
respiratory arousals or frequency of periodic limb movement
arousals between those with combat-related PTSD and those with
sleep-disturbed, non-PTSD military individuals.
In this study of CF veterans with chronic post-combat PTSD,
a prolonged delay in the onset to REM sleep is accompanied by
negative mood and negative cognitive symptoms. Whereas most
tricyclic, SSRI and SNRI antidepressant drugs may reduce and
delay the onset to REM sleep,31 the delay in onset to REM sleep
persists when the use of antidepressants, as well as anticonvulsants
and psychotropic drugs, is statistically controlled. A previous sleep
EEG study, however, that compared the sleep of drug-free combat-
related PTSD patients with patients with major depression and
normal individuals showed that the PTSD group had similar
reduction in REM sleep and no delay in onset to REM sleep.36
Overall, our results are supportive of Germain’s hypothesis and
previous EEG sleep research that disturbed REM and non-REM sleep
contribute to maladaptive stress and trauma responses in PTSD.38
Ideally, further studies of sleep physiology should involve
comparisons between a group of non-sleep-altering medicated
sleep-disturbed individuals with PTSD and age-matched normal
healthy sleepers who are acclimatised to the novelty of the
laboratory environment. To affirm the importance of a disorganisa-
tion of the REM/non-REM sleep as a possible key factor to the
emergence of PTSD, it would be preferable to examine the EEG
sleep before any drug administration, which may influence sleep
physiology. The design of the research did not permit a comparative
study with those who had benefitted from specific pharmacological
and/or behavioural treatment. A future study employing similar
physiological and behavioural methodology should comprise a large
group of randomised, early-identified combat-exposed versus non-
combat-exposed individuals who are free of potentially sleep EEG
confounding psychotropic drugs. Such research may pave the way
to determining what pharmacological and behavioural methods
would be useful in those early-detected post-combat military
with PTSD.
Our decision to include measures of negative cognition and
mood in patients with PTSD, diagnosed by DSM-IV criteria,
Table 3 Physical self-reports
PTSD
No Yes
Dependent LSM SE n LSM SE n P
Pre-sleep sleepiness 2.94 0.14 53 2.99 0.20 33 NS
Post-sleep sleepiness 3.03 0.14 51 3.27 0.19 34 NS
Pre-sleep fatigue 3.67 0.20 53 4.38 0.28 33 NS
Post-sleep fatigue 2.93 0.18 51 3.88 0.24 34 <0.01
Pre-sleep pain 3.02 0.51 52 5.25 0.71 34 NS
Post-sleep pain 3.19 0.57 51 5.16 0.78 34 NS
Somatic symptoms (WPSI) 5.44 0.63 57 10.15 0.88 37 <0.001
All P-values from ranked (non-parametric) tests are adjusted by the adaptive Holm method to control family-wise error rate. Least-square means (LSM) for PTSD, no (0) and yes (1), are
adjusted to remove combat effect. Bold denotes significance.
Table 4 Results of ANOVAs on raw and ranked data for SCL-90 subscales for paranoid, hostility and BDI psychological self-reports
PTSD
No Yes
Dependent LSM SE n LSM SE n P
Hostility score 3.02 0.63 53 6.56 0.84 36 <0.001
Paranoid score 2.05 0.48 56 5.68 0.66 35 <0.0001
BDI score 9.88 1.05 56 22.74 1.47 36 <0.0001
All P-values from ranked (non-parametric) tests are adjusted by the adaptive Holm method to control family-wise error rate. Least-square means (LSM) for PTSD, ‘no’ (0) and ‘yes’ (1), are
adjusted to remove combat effects. Bold denotes significance.
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highlights their importance in the current DSM-5 criteria. This
finding highlights the importance of paranoid and hostile
behaviour in those with PTSD following a major traumatic
experience.6 Their presence in these veterans with chronic PTSD,
despite their various drug and behavioural treatments, may stem
from an inability in civilian life to overcome their combat-ready
vigilant mindset, which becomes ingrained in military training.
Such cognitive and behavioural abnormalities may contribute to
the increased prevalence of dysfunctional domestic and social
behaviour in U.S. veterans with PTSD,39 and in post-combat
British veterans.40
In conclusion, the results of this study and previous clinical
research support the notion that chronic disturbed sleep physiol-
ogy, unexplained musculoskeletal pain and fatigue symptoms
should be considered to be integral to irremediable post-combat
PTSD. Moreover, paranoid and hostile ideation among those with
post-combat PTSD, as well as in civilians with PTSD,6 may be a
cautionary signal to the potential for antisocial behaviour. Further
studies are needed to determine whether civilians who are victims
of psychologically stressful events (e.g. sexual assault, non-
physically injurious MVA, and industrial and environmental
disasters) may demonstrate similar distinguishing features that
predispose to PTSD as noted in Fig. 1.
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